IDH1 genotyping is frequently accomplished via IHC in other cancers such as glioma, but NGS is the preferred method in CCA as it enables simultaneous detection of actionable alterations in FGFR2, NTRK, RET, and BRAF [4,92]. This evidence concerns the gene IDH1 and cholangiocarcinoma.